Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.78 |
| ▸ | PPARA | Q07869 | 16/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496192 | 0.88 | PPARG (1.00) | PPARGPPARASIGMAR1NPC1LMNA | |
| SCHEMBL5913603 | 0.88 | PPARG (1.00) | PPARGPPARASIGMAR1NPC1LMNA | |
| SCHEMBL5892219 | 0.88 | PPARG (0.76) | PPARGPPARASIGMAR1 | |
| SCHEMBL5892210 | 0.87 | PPARG (0.85) | PPARGPPARASIGMAR1NPC1LMNA | |
| SCHEMBL5913369 | 0.87 | PPARG (0.95) | PPARGPPARASIGMAR1NPC1LMNA | |
| SCHEMBL5423502 | 0.87 | PPARG (0.69) | PPARGPPARANPC1LMNARAB9A | |
| SCHEMBL5423510 | 0.87 | PPARG (0.69) | PPARGPPARANPC1LMNARAB9A | |
| SCHEMBL5892233 | 0.86 | PPARG (0.76) | PPARGPPARASIGMAR1 | |
| SCHEMBL5421678 | 0.86 | PPARG (0.68) | PPARGPPARANPC1LMNARAB9A | |
| SCHEMBL5421675 | 0.86 | PPARG (0.68) | PPARGPPARANPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071221-B2 | Heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2006-07-04 | — | — | US | disclosed |
| US-20050026973-A1 | New heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026973-A1 | New heterocyclic oxime compounds | CBR3, CBR1, CYB5R3 | PPARG 785/4885PPARA 1112/4885SIGMAR1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.